Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6661 to 6675 of 8223 results

  1. Interstitial cystitis: oral pentosan polysulfate sodium (ESUOM43)

    This guidance has been updated and replaced by NICE technology appraisal guidance 610.

  2. Parkinson's disease with motor fluctuations: safinamide (ES6)

    This evidence summary has been updated and replaced by NICE guideline NG71.

  3. Peezy Midstream for urine collection (MIB183)

    NICE has withdrawn the med tech innovation briefing (MIB) on Peezy Midstream for urine collection.

  4. Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1038.

  5. Maternal and child nutrition (PH11)

    This guideline has been updated and replaced by NICE guideline NG247.

  6. Weight management: lifestyle services for overweight or obese children and young people (PH47)

    This guideline has been updated and replaced by NICE guideline NG246.

  7. Weight management: lifestyle services for overweight or obese adults (PH53)

    This guideline has been updated and replaced by NICE guideline NG246.

  8. Obesity: working with local communities (PH42)

    This guideline has been updated and replaced by NICE guideline NG246.

  9. Preventing excess weight gain (NG7)

    This guideline has been updated and replaced by NICE guideline NG246.

  10. Obesity: identification, assessment and management (CG189)

    This guideline has been updated and replaced by NICE guideline NG246.

  11. Obesity prevention (CG43)

    This guideline has been updated and replaced by NICE guideline NG246.

  12. Liquid-based cytology for cervical screening (TA5)

    This guidance has been replaced by NICE technology appraisal guidance 69.

  13. Management of aggression, agitation and behavioural disturbances in dementia: valproate preparations (ESUOM41)

    This evidence summary has been updated and replaced by NICE guideline NG97.

  14. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1042